HCWB (HCW Biologics) Quality Rank


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $4.30
GF Value $43.79
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

HCW Biologics Quality Rank Related Terms

HCWB
39GF Score
HCW Biologics Inc HCWB
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $4.30 is trading 90.2% below its estimated GF Value™ of $43.79. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Quality Rank:
  • GF Value™: $43.79 vs. price of $4.30 (90.2% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price
$43.79
GF Value